Table of Contents Author Guidelines Submit a Manuscript
Journal of Addiction
Volume 2016, Article ID 9298571, 11 pages
http://dx.doi.org/10.1155/2016/9298571
Research Article

Nonmedical Use of Antihistaminergic Anxiolytics and Other Prescription Drugs among Persons with Opioid Dependence

1Department of Clinical Sciences Lund, Psychiatry, Faculty of Medicine, Lund University, Lund, Sweden
2Malmo Addiction Centre, Malmo, Sweden
3Behavioral and Urban Health Program, RTI International, San Francisco, CA, USA

Received 23 September 2016; Accepted 27 November 2016

Academic Editor: Gallus Bischof

Copyright © 2016 Disa Dahlman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Casati, R. Sedefov, and T. Pfeiffer-Gerschel, “Misuse of medicines in the European union: a systematic review of the literature,” European Addiction Research, vol. 18, no. 5, pp. 228–245, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. L. DuPont, “Prescription drug abuse: an epidemic dilemma,” Journal of Psychoactive Drugs, vol. 42, no. 2, pp. 127–132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. H. Hernandez and L. S. Nelson, “Prescription drug abuse: insight into the epidemic,” Clinical Pharmacology and Therapeutics, vol. 88, no. 3, pp. 307–317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Brands, J. Blake, D. C. Marsh, B. Sproule, R. Jeyapalan, and S. Li, “The impact of benzodiazepine use on methadone maintenance treatment outcomes,” Journal of Addictive Diseases, vol. 27, no. 3, pp. 37–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. F. J. Eiroa-Orosa, C. Haasen, U. Verthein, C. Dilg, I. Schäfer, and J. Reimer, “Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the german randomized controlled trial,” Drug and Alcohol Dependence, vol. 112, no. 3, pp. 226–233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Jones, S. Mogali, and S. D. Comer, “Polydrug abuse: a review of opioid and benzodiazepine combination use,” Drug and Alcohol Dependence, vol. 125, no. 1-2, pp. 8–18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Lintzeris and S. Nielsen, “Benzodiazepines, methadone and buprenorphine: interactions and clinical management,” American Journal on Addictions, vol. 19, no. 1, pp. 59–72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Vogel, B. Knöpfli, O. Schmid et al., “Treatment or ‘high’: benzodiazepine use in patients on injectable heroin or oral opioids,” Addictive Behaviors, vol. 38, no. 10, pp. 2477–2484, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Abrahamsson, C. Widinghoff, A. Lilliebladh, C. Gedeon, K. Nilvall, and A. Hakansson, “Interim buprenorphine treatment in opiate dependence: a pilot effectiveness study,” Substance Abuse, vol. 37, no. 1, pp. 104–109, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. W. M. Compton, C. M. Jones, and G. T. Baldwin, “Relationship between nonmedical prescription-opioid use and heroin use,” New England Journal of Medicine, vol. 374, no. 2, pp. 154–163, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. T. E. Wilens, L. A. Adler, J. Adams et al., “Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 47, no. 1, pp. 21–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. E. Albertson, J. A. Chenoweth, D. K. Colby, and M. E. Sutter, “The changing drug culture: use and misuse of cognition-enhancing drugs,” FP Essentials, vol. 441, pp. 25–29, 2016. View at Google Scholar
  13. D. B. Clemow and D. J. Walker, “The potential for misuse and abuse of medications in ADHD: a review,” Postgraduate medicine, vol. 126, no. 5, pp. 64–81, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Helander, Y. Al-Saffar, C. Heidenfors, and C. Kuttim, “‘You will only get answers to the questions you ask’. New drugs require new testing procedures,” Lakartidningen, vol. 110, no. 6, pp. 256–257, 2013 (Swedish). View at Google Scholar
  15. E. Frauger, D. Amaslidou, M. Spadari et al., “Patterns of methylphenidate use and assessment of its abuse among the general population and individuals with drug dependence,” European Addiction Research, vol. 22, no. 3, pp. 119–126, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Bannan, S. Rooney, and J. O'Connor, “Zopiclone misuse: an update from Dublin,” Drug and Alcohol Review, vol. 26, no. 1, pp. 83–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Hajak, W. E. Müller, H. U. Wittchen, D. Pittrow, and W. Kirch, “Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data,” Addiction, vol. 98, no. 10, pp. 1371–1378, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Grosshans, T. Lemenager, C. Vollmert et al., “Pregabalin abuse among opiate addicted patients,” European Journal of Clinical Pharmacology, vol. 69, no. 12, pp. 2021–2025, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Schifano, “Misuse and abuse of pregabalin and gabapentin: cause for concern?” CNS Drugs, vol. 28, no. 6, pp. 491–496, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. McNamara, S. Stokes, R. Kilduff, and A. Shine, “Pregabalin abuse amongst opioid substitution treatment patients,” Irish Medical Journal, vol. 108, no. 10, pp. 309–310, 2015. View at Google Scholar · View at Scopus
  21. T. Wilens, C. Zulauf, D. Ryland, N. Carrellas, and I. Catalina-Wellington, “Prescription medication misuse among opioid dependent patients seeking inpatient detoxification,” The American Journal on Addictions, vol. 24, no. 2, pp. 173–177, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. C. R. W. Baird, P. Fox, and L. A. Colvin, “Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers,” European Addiction Research, vol. 20, no. 3, pp. 115–118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. B. J. Shapiro, K. L. Lynch, T. Toochinda, A. Lutnick, H. Y. Cheng, and A. H. Kral, “Promethazine misuse among methadone maintenance patients and community-based injection drug users,” Journal of Addiction Medicine, vol. 7, no. 2, pp. 96–101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. K. L. Lynch, B. J. Shapiro, D. Coffa, S. P. Novak, and A. H. Kral, “Promethazine use among chronic pain patients,” Drug and Alcohol Dependence, vol. 150, pp. 92–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. M. E. Tsay, G. Procopio, B. D. Anderson, and W. Klein-Schwartz, “Abuse and intentional misuse of promethazine reported to US poison centers: 2002 to 2012,” Journal of Addiction Medicine, vol. 9, no. 3, pp. 233–237, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. S.-H. Jo, H.-K. Hong, S. H. Chong, H. S. Lee, and H. Choe, “H1 antihistamine drug promethazine directly blocks hERG K+ channel,” Pharmacological Research, vol. 60, no. 5, pp. 429–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. B. Page, S. B. Duffull, I. M. Whyte, and G. K. Isbister, “Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal,” QJM, vol. 102, no. 2, pp. 123–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Darke and D. Zador, “Fatal heroin 'overdose': a review,” Addiction, vol. 91, no. 12, pp. 1765–1772, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Warner-Smith, S. Darke, M. Lynskey, and W. Hall, “Heroin overdose: causes and consequences,” Addiction, vol. 96, no. 8, pp. 1113–1125, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. D. J. Sanger, “The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents,” CNS Drugs, vol. 18, no. 1, pp. 9–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. D. M. Reith, J. Fountain, R. McDowell, and M. Tilyard, “Comparison of the fatal toxicity index of zopiclone with benzodiazepines,” Journal of Toxicology—Clinical Toxicology, vol. 41, no. 7, pp. 975–980, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Zaccara, P. Gangemi, P. Perucca, and L. Specchio, “The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials,” Epilepsia, vol. 52, no. 4, pp. 826–836, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. P. Zacny, J. A. Paice, and D. W. Coalson, “Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers,” Pharmacology Biochemistry and Behavior, vol. 100, no. 3, pp. 560–565, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Häkkinen, E. Vuori, E. Kalso, M. Gergov, and I. Ojanperä, “Profiles of pregabalin and gabapentin abuse by postmortem toxicology,” Forensic Science International, vol. 241, pp. 1–6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. C. K. Aitken and P. Higgs, “Severe vein damage caused by Temezepam injecting,” Australian and New Zealand Journal of Public Health, vol. 26, no. 1, article 79, 2002. View at Google Scholar · View at Scopus
  36. G. F. X. Feeney and H. H. Gibbs, “Digit loss following misuse of temazepam,” Medical Journal of Australia, vol. 176, no. 8, p. 380, 2002. View at Google Scholar · View at Scopus
  37. T. A. Partanen, P. Vikatmaa, E. Tukiainen, M. Lepäntalo, and J. Vuola, “Outcome after injections of crushed tablets in intravenous drug abusers in the Helsinki University Central Hospital,” European Journal of Vascular and Endovascular Surgery, vol. 37, no. 6, pp. 704–711, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. K. S. Yeo, C.-Y. Chan, and K.-H. Chia, “Complications relating to intravenous buprenorphine abuse: a single institution case series,” Annals of the Academy of Medicine Singapore, vol. 35, no. 7, pp. 487–491, 2006. View at Google Scholar · View at Scopus
  39. M. M. Glatt, “Uses and abuses of chlormethiazole,” The Lancet, vol. 1, no. 8125, pp. 1093–1094, 1979. View at Google Scholar
  40. E. Vittinghoff and C. E. McCulloch, “Relaxing the rule of ten events per variable in logistic and cox regression,” American Journal of Epidemiology, vol. 165, no. 6, pp. 710–718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. IBM Corp, Released 2013. IBM SPSS Statistics for Windows, Version 22.0, IBM Corp [Computer Program], Armonk, NY, USA, 2013.
  42. J. P. Zacny and S. A. Lichtor, “Nonmedical use of prescription opioids: motive and ubiquity issues,” Journal of Pain, vol. 9, no. 6, pp. 473–486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Kapil, J. L. Green, M.-C. Le Lait, D. M. Wood, and P. I. Dargan, “Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK,” British Journal of Clinical Pharmacology, vol. 78, no. 1, pp. 190–191, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Sharma and S. K. Mattoo, “Buprenorphine abuse in India: an update,” Indian Journal of Psychiatry, vol. 41, no. 2, pp. 154–159, 1999. View at Google Scholar
  45. M. Clatts, L. M. Giang, L. Goldsamt, and V. Colón-López, “Nonmedical use of promethazine hydrochloride among heroin injectors in vietnam: unrecognized risks and unintended consequences,” Substance Use and Misuse, vol. 45, no. 4, pp. 515–527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. P. Ojha, S. Sigdel, H.-G. Meyer-Thompson, H. Oechsler, and U. Verthein, “‘South Asian cocktail’—the concurrent use of opioids, benzodiazepines and antihistamines among injecting drug users in Nepal and associations with HIV risk behaviour,” Harm Reduction Journal, vol. 11, article 17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Kraus, R. Augustin, M. Frischer, P. Kümmler, A. Uhl, and L. Wiessing, “Estimating prevalence of problem drug use at national level in countries of the European Union and Norway,” Addiction, vol. 98, no. 4, pp. 471–485, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Been, L. Bijlsma, L. Benaglia et al., “Assessing geographical differences in illicit drug consumption—a comparison of results from epidemiological and wastewater data in Germany and Switzerland,” Drug and Alcohol Dependence, vol. 161, pp. 189–199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. J. C. Maxwell and B. A. Rutkowski, “The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992–2007,” Drug and Alcohol Review, vol. 27, no. 3, pp. 229–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Vrecko, “Everyday drug diversions: a qualitative study of the illicit exchange and non-medical use of prescription stimulants on a university campus,” Social Science and Medicine, vol. 131, pp. 297–304, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. S. E. McCabe, J. R. Knight, C. J. Teter, and H. Wechsler, “Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey,” Addiction, vol. 100, no. 1, pp. 96–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. G. D. Bjarnadottir, H. M. Haraldsson, B. O. Rafnar et al., “Prevalent intravenous abuse of methylphenidate among treatment-seeking patients with substance abuse disorders: a descriptive population-based study,” Journal of Addiction Medicine, vol. 9, no. 3, pp. 188–194, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kaye, J. A. Ramos-Quiroga, G. van de Glind et al., “Persistence and subtype stability of ADHD among substance use disorder treatment seekers,” Journal of Attention Disorders, 2016. View at Publisher · View at Google Scholar
  54. K. van Emmerik-van Oortmerssen, G. van de Glind, W. van den Brink et al., “Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis,” Drug and Alcohol Dependence, vol. 122, no. 1-2, pp. 11–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. G. Martinotti, M. Lupi, F. Sarchione et al., “The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview,” Current Pharmaceutical Design, vol. 19, no. 35, pp. 6367–6374, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. S. E. Back, R. L. Payne, A. N. Simpson, and K. T. Brady, “Gender and prescription opioids: Findings from the National Survey on Drug Use and Health,” Addictive Behaviors, vol. 35, no. 11, pp. 1001–1007, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. W. C. Becker, L. E. Sullivan, J. M. Tetrault, R. A. Desai, and D. A. Fiellin, “Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates,” Drug and Alcohol Dependence, vol. 94, no. 1–3, pp. 38–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Huang, D. A. Dawson, F. S. Stinson et al., “Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions,” Journal of Clinical Psychiatry, vol. 67, no. 7, pp. 1062–1073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Bråbäck, S. Nilsson, P. Isendahl, K. Troberg, L. Brådvik, and A. Håkansson, “Malmö Treatment Referral and Intervention Study (MATRIS)—effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial,” Addiction, vol. 111, no. 5, pp. 866–873, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Abrahamsson, “Benzodiazepine, z-drug and pregabalin prescription and mortality among patients in opioid maintenance treatment – a nation-wide register-based open cohort study,” in Use and Misuse of Sedative Drugs and Related Substances: Findings in the General Population and in Individuals with Opioid Dependence, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden, 2015. View at Google Scholar